JGC
NERV icon

J. Goldman & Co’s Minerva Neurosciences NERV Stock Holding History

J. Goldman & Co’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-7,277
Closed -$350K – 316
2020
Q1 		$350K Sell
7,277
-23,973
-77% -$1.45M 0.04% 193
2019
Q4 		$1.78M Buy
+31,250
New +$1.38M 0.13% 150
2017
Q4 		– Sell
-19,590
Closed -$1.19M – 407
2017
Q3 		$1.19M Sell
19,590
-37,285
-66% -$2.14M 0.06% 229
2017
Q2 		$4.03M Buy
56,875
+52,725
+1,270% +$3.41M 0.22% 121
2017
Q1 		$269K Sell
4,150
-8,760
-68% -$680K 0.01% 295
2016
Q4 		$1.21M Sell
12,910
-2,280
-15% -$233K 0.08% 208
2016
Q3 		$1.72M Buy
15,190
+2,573
+20% +$250K 0.1% 193
2016
Q2 		$1.03M Buy
+12,617
New +$802K 0.05% 254

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

J. Goldman & Co's NERV Position: Q2 2020 in Review

J. Goldman & Co sold out of Minerva Neurosciences (NERV) in Q2 2020, closing a stake of 7,277 shares — an estimated $350K sold.

J. Goldman & Co first reported a position in NERV in Q2 2016 and held it in 8 quarters. The position peaked at $4.03M in Q2 2017. 80 funds tracked by Wall St. Rank hold NERV as of Q2 2020.

  • J. Goldman & Co reported no remaining Minerva Neurosciences position as of Q2 2020 after selling out during the quarter.
  • J. Goldman & Co sold 7,277 Minerva Neurosciences shares in Q2 2020, an estimated $350K.
  • J. Goldman & Co first reported a position in Minerva Neurosciences in Q2 2016 and held it in 8 quarters.
  • J. Goldman & Co's Minerva Neurosciences position peaked at $4.03M in Q2 2017.
  • 80 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q2 2020.

Based on J. Goldman & Co's 13F filing for Q2 2020, filed 14 Aug 2020.